The ability of sorafenib to inhibit oncogenic PDGFR beta and FLT3 mutants and overcome resistance to other small molecule inhibitors

Background and Objectives Activated tyrosine kinases are implicated in the pathogenesis of chronic and acute leukemia, and represent attractive targets for therapy. Sorafenib (BAY43-9006, Nexavar (R)) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families. We investigated the efficacy of sorafenib at inhibiting mutants of the receptor tyrosine kinases PDGFR beta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies. Design and Methods We tested the effect of sorafenib on the proliferation of hematopoietic cells transformed by ETV6-PDGFR beta, FLT3 with an internal tandem duplication or D835Y point mutation, and the KIT(D816V) mutant. The direct effect of sorafenib on the activity of these kinases and their downstream signaling was tested using phospho-specific antibodies. Results We show that sorafenib is a potent inhibitor of ETV6-PDGFR beta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors. Sorafenib induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing FLT3 with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines. The imatinib-resistant KIT(D816V) mutant, associated with systemic mastocytosis, was found to be resistant to sorafenib. Interpretation and Conclusions These results warrant further clinical studies of sorafenib for the treatment of myeloid malignancies expressing activated forms of PDGFR beta and FLT3.